At Last! Applying the National Hypertension Guidelines in Special Populations

Karen J. McConnell, Pharm.D., ASH-CHC, BCPS-AQ Cardiology, FCCP
System Director, Clinical Pharmacy Services
Catholic Health Initiatives, Englewood, CO

Joel Marrs, Pharm.D., BCACP, BCPS-AQ Cardiology, CLS, FAHA, FASHP, FCCP, FNLA
Associate Professor
University of Colorado, Aurora, CO
Disclosures

All planners, presenters, reviewers, and ASHP staff of this session report no financial relationships relevant to this activity.
Learning Objectives

• Describe the population at risk for developing hypertension (HTN) and current blood pressure control rates.
• Develop optimal blood pressure goals for a patient with HTN and co-morbid conditions according to practice guidelines and clinical trial evidence.
• Demonstrate appropriate drug selection for the treatment of HTN according to concomitant conditions and compelling indications.
• Devise an evidence-based treatment strategy for resistant HTN to achieve blood pressure goals.
2017 ACC/AHA Hypertension Guidelines
General Updates

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for
the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults,
Major HTN Practice Guidelines

- JNC 7 (2002)
- KDIGO, chronic kidney disease (2012)
- Recommendations from former JNC 8 panel (2013; not sanctioned by NHLBI)
- ASH/ISH (2013)
- AHA/ASA Stroke guidelines (2014)

- AHA/ACC/ASH HTN and CAD guidelines (2015)
- ADA Standards of Medical Care in diabetes (2018)
- ACC/AHA/HFSA Heart failure guidelines update (2017)
- ACC/AHA/APhA/ASH High Blood Pressure in Adults guideline (2017)
- ESC/ESH HTN guidelines (2018)
- AHA Scientific Statement on Resistant HTN (2018)
Show of Hands

How many of you are familiar with the 2017 ACC/AHA BP Guidelines?

- A Very. I use them every single day
- B Mostly, I treat HTN regularly
- C Fairly, I’ve reviewed them
- D Not, please teach me
2017 BP Guideline

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA
Guideline for the Prevention, Detection, Evaluation, and Management
of High Blood Pressure in Adults

A Report of the American College of Cardiology/American Heart Association Task Force on
Clinical Practice Guidelines

WRITING COMMITTEE MEMBERS
Paul K. Whelton, MB, MD, MSc, FAHA, Chair
Robert M. Carey, MD, FAHA, Vice Chair
Wilbert S. Aronow, MD, FACC, FAHA*
Donald E. Casey, Jr., MD, MPH, MBA, FAHA†
Karen J. Collins, MBS‡
Cheryl Dennison Himmelfarb, RN, ANP, PhD, FAHA$
Sandra M. DePalma, MHS, PA-C, CLS, AACC||
Samuel Gidding, MD, FACC, FAHA&&
Kenneth A. Jamerson, MD#
Daniel W. Jones, MD, FAHA†
Eric J. Maclachlin, PharmD**
Paul Muntner, PhD, FAHA†

ACC/AHA TASK FORCE MEMBERS
Glenn N. Levine, MD, FACC, FAHA, Chair
Patrick T. O’Gara, MD, MACC, FAHA, Chair-Elect
Jonathan L. Halperin, MD, FACC, FAHA, Immediate Past Chair

Sana A. Akhatib, MD, MHS, FACC, FAHA
Joshua A. Beckman, MD, MS, FAHA
Kim K. Birkner, MS, PharmD, AACC
Blythm Bokurto, MD, PhD, FACC, FAHA***
Ralph G. Brindis, MD, MPH, MACC***
Joaquin E. Cigarsa, MD, FACC
Lesley H. Curtis, PhD, FAHA***
Anita Deswal, MD, MPH, FACC, FAHA
Lee A. Fleisher, MD, FACC, FAHA
Duminda N. Wijeyseundera, MD, PhD

* Bruce Ovbiagele, MD, MSc, MAS, MBA, FAHA†
† Sidney C. Smith, Jr., MD, MACC, FAHA††
‡ Crystal C. Spencer, JD
§ Randall S. Stafford, MD, PhD‡‡
‖ Sandra J. Talier, MD, FAHA§§
¶ Randall J. Thomas, MD, MS, FACC, FAHA
‖‖ Kim A. Williams, Sr, MD, MACC, FAHA
¶¶ Jeff D. Williamson, MD, MHS¶¶
## Jackson T. Wright, Jr, MD, PhD, FAHA##
Systematic Review Questions

1. Is there evidence that self-directed monitoring of BP and/or ambulatory BP monitoring are superior to office-based measurement of BP by a healthcare worker for
   a. preventing adverse outcomes for which high BP is a risk factor
   b. achieving better BP control?
2. What is the optimal target for BP lowering during antihypertensive therapy in adults?
3. In adults with hypertension, do various antihypertensive drug classes differ in their comparative benefits and harms?
4. In adults with hypertension, does initiating treatment with antihypertensive pharmacological monotherapy versus initiating treatment with 2 drugs (including fixed dose combination therapy), either of which may be followed by the addition of sequential drugs, differ in comparative benefits and/or harms on specific health outcomes?
Hypertension

- **Definition**

  BP should be categorized as normal, elevated, or stage 1 or 2 hypertension to prevent and treat high BP

<table>
<thead>
<tr>
<th>BP Category</th>
<th>SBP</th>
<th>DBP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>&lt; 120 mm Hg</td>
<td>&lt; 80 mm Hg</td>
</tr>
<tr>
<td>Elevated</td>
<td>120-129 mm Hg</td>
<td>&lt; 80 mm Hg</td>
</tr>
<tr>
<td>Hypertension</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage 1</td>
<td>130-139 mm Hg</td>
<td>80-89 mm Hg</td>
</tr>
<tr>
<td>Stage 2</td>
<td>≥ 140 mm Hg</td>
<td>≥ 90 mm Hg</td>
</tr>
</tbody>
</table>
Prevalence of High BP

≥ 130/80 mm Hg or taking antihypertensive therapy

- Overall: 46%
  - Men: 48%, Women: 43%
- Prevalence increases with age

- Prevalence highest in non-Hispanic black people
  - Men: 59%, Women: 56%

<table>
<thead>
<tr>
<th>Age (y)</th>
<th>Men</th>
<th>Women</th>
</tr>
</thead>
<tbody>
<tr>
<td>20-44</td>
<td>30%</td>
<td>19%</td>
</tr>
<tr>
<td>55-64</td>
<td>70%</td>
<td>63%</td>
</tr>
<tr>
<td>75+</td>
<td>79%</td>
<td>85%</td>
</tr>
</tbody>
</table>

≥ 140/90 mm Hg or taking antihypertensive therapy

- Overall: 32%
  - Men: 31%, Women: 32%
- Prevalence increases with age

- Prevalence highest in non-Hispanic black people
  - Men: 42%, Women: 46%

<table>
<thead>
<tr>
<th>Age (y)</th>
<th>Men</th>
<th>Women</th>
</tr>
</thead>
<tbody>
<tr>
<td>20-44</td>
<td>11%</td>
<td>10%</td>
</tr>
<tr>
<td>55-64</td>
<td>53%</td>
<td>52%</td>
</tr>
<tr>
<td>75+</td>
<td>71%</td>
<td>78%</td>
</tr>
</tbody>
</table>
# BP Thresholds and Goals – General

<table>
<thead>
<tr>
<th>Clinical Condition</th>
<th>BP Threshold, mm Hg</th>
<th>BP Goal, mm Hg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical CVD or 10-year ASCVD risk ≥10%</td>
<td>≥130/80</td>
<td>&lt;130/80</td>
</tr>
<tr>
<td>No clinical CVD and 10-year ASCVD risk &lt;10%</td>
<td>≥140/90</td>
<td>&lt;130/80</td>
</tr>
<tr>
<td>Older persons (≥65 years; noninstitutionalized, ambulatory, community-living)</td>
<td>≥130 (SBP)</td>
<td>&lt;130 (SBP)</td>
</tr>
</tbody>
</table>
Blood Pressure Goal Trials

- SPRINT trial (2015)
  - Cited in 2017 HF focused update and 2017 ACC/AHA HTN guidelines as justification for lower BP goals
- Meta-analysis comparing BP levels and CVD risk (2017)
SPRINT Trial (2015)

- Randomized Trial of Intensive versus Standard Blood-Pressure Control
  - 9300 people aged 50 years or old without diabetes or previous TIA/stroke
  - Baseline SBP 130-180 mm Hg with increased CV risk
  - Randomized to either SBP goal <120 mm Hg or <140 mm Hg
  - Primary outcome: Composite MI, acute coronary syndrome, acute decompensated heart failure, death from CV causes

doi: 10.1056/NEJMoA1511939
SPRINT Trial (2015)

• Results
  – Intensive control reduced the primary outcome
    • 1.65% per year vs. 2.19% per year
    • Hazard ratio 0.75; 95% confidence interval [CI], 0.64–0.89; p<0.001
    • Number needed to treat = 61.
    • Benefits also occurred in patients older than 75.
  – Adverse reactions in intensive arm
    • Increased rates of hypotension, syncope, electrolyte abnormalities, and acute kidney injury/failure
    • Number needed to harm = 100 for hypotension.

doi: 10.1056/NEJMoa1511939
Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality

- Assessed the association of mean achieved SBP levels with the risk of CVD and all-cause mortality in adults with HTN treated with antihypertensive therapy
- Over 144,000 patients from 42 trials were included
- Linear association between mean achieved SBP and risk of CVD and mortality were seen
- Authors concluded that reducing SBP to levels below currently recommended goals could significantly reduce CVD and all-cause mortality

JAMA Cardiol. 2017;2(7):775-81.
Major CVD and All-Cause Mortality
Associated with More Intensive Reductions in Systolic Blood Pressure

Major CVD: Compared to 120-124 mm Hg
130 to 135 mm Hg; HR 0.71 (95% CI 0.60-0.83)
140 to 144 mm Hg; HR 0.58 (95% CI 0.48-0.72)
150 to 154 mm Hg; HR 0.46 (95% CI 0.34-0.63)
Greater than 160 mm Hg; HR 0.36 (95% CI 0.26-0.51)

All-cause mortality: Compared to 120-124 mm Hg
130 to 135 mm Hg; HR 0.73 (95% CI 0.58-0.93)
140 to 144 mm Hg; HR 0.59 (95% CI 0.45-0.77)
150 to 154 mm Hg; HR 0.51 (95% CI 0.36-0.71)
Greater than 160 mm Hg; HR 0.47 (95% CI 0.32-0.67)

JAMA Cardiol. 2017;2(7):775-781.
Initiation of antihypertensive drug therapy with 2 first-line agents of different classes, either as separate agents or in a fixed-dose combination, is recommended in adults with stage 2 HTN and an average BP >20/10 mm Hg above their BP target.
For initiation of antihypertensive drug therapy, **first-line agents** include thiazide diuretics, CCBs, and ACE inhibitors or ARBs.

In **black adults** with HTN but without HF or CKD, including those with DM, initial antihypertensive treatment should include a thiazide-type diuretic or CCB.

Simultaneous use of an ACE inhibitor, ARB, and/or renin inhibitor is potentially harmful and is not recommended to treat adults with HTN.
Hypertension and Diabetes
Patient Case: AS

• AS is a 67 year old white woman with diabetes. She has been told in the past that her blood pressure is “a little high,” but she has never been on BP medications or bought a home BP monitor.
• Social History: nonsmoker; no alcohol; walks for 30 minutes 3x/week; follows a low carb diet
• Medications:
  – Atorvastatin 40 mg daily
  – Metformin 1 g twice daily
  – Empagliflozin 25 mg daily
  – Omeprazole 40 mg daily
Patient Case: AS

- Reports adherence with all medications
- Labs and vitals:
  - BP 138/88 mm Hg (138/84 repeat), HR 80 bpm
  - A1C 6.7%; SCr is 1.3 mg/dL (CrCl [adjusted BW] 46.8 ml/min), K 4.1 mEq/L, Na 135 mEq/L, no proteinuria, other labs are normal
  - BMI 33.4 kg/m²
- When discussing her BP, she said she was grateful that her BP is still at goal today
What is AS’s BP goal?

A. < 120/80 mm Hg
B. < 130/80 mm Hg
C. < 140/90 mm Hg
D. < 150/90 mm Hg
How should her BP be addressed?

A. Start lisinopril 10 mg/day
B. Start chlorthalidone 12.5 mg/day
C. Start amlodipine 5 mg/day
D. Dealer’s choice, all of the above are correct
Diabetes Mellitus

• Most patients with diabetes are affected by HTN
  – Prevalence of HTN among adults with DM is approximately 80%
  – HTN is at least twice as common in persons with type 2 DM than in age-matched individuals without DM
• HTN is a risk factor for macro- and microvascular complications
  – Results in higher incidence of CHD, HF, PAD, stroke, CVD mortality
  – May increase risk of nephropathy and retinopathy
• Because CVD is the #1 killer of, and main source of morbidity in, patients with diabetes, controlling CV risk factors such as HTN in patients with diabetes is of utmost importance.
ACCORD Trial (2010)

• Action to Control Cardiovascular Risk in Diabetes blood pressure trial
  – 4700 patients with Type 2 diabetes who had CVD or at least 2 additional CVD risk factors
  – Mean baseline BP was 139/76 mm Hg
  – Randomized to either SBP goal <120 mm Hg or <140 mm Hg
  – Primary composite outcome (nonfatal MI, nonfatal stroke, or death from CV causes)

• Results, after 4.7 year follow-up period
  – Mean SBP for intensive group: 119.3 mm Hg
  – Mean SBP for standard group: 133.5 mm Hg

ACCORD Trial (2010)

• Results
  – No significant different in rate of primary outcome for intensive vs. standard therapy
    • 1.87% vs. 2.09%; HR 0.88; 95% CI, 0.73–1.06
  – No difference in all-cause mortality or CV death
  – Intensive therapy was associated with less stroke (0.32% vs. 0.53%; HR 0.59; 95% CI, 0.39–0.89)
  – Serious adverse events from antihypertensive drugs occurred significantly more often in the intensive therapy group
    • For example, hypotension, syncope, bradycardia, electrolyte abnormalities, angioedema, and renal failure

Guideline Response to ACCORD

• The ACCORD trial was underpowered to detect a statistically significant difference between the 2 treatment arms.
• The ACCORD trial demonstrated a small reduction in absolute risk (1.1%) for stroke, but there were few such events.
• More adverse events (2% increase in absolute risk) were identified in the lower BP group, especially self-reported hypotension and a reduction in estimated GFR, but these did not result in an excess of stroke or ESRD.
• The ACCORD trial was a factorial study
  – Secondary analysis demonstrated a significant outcome benefit in the intensive BP/standard glycemic group
  – Benefit in the intensive BP/intensive glycemic control group was no better than in the intensive BP/standard glycemic control group
  – Suggests a floor benefit beyond which the combined intensive interventions were ineffective
• An ACCORD secondary analysis suggested that an SBP <120 mm Hg is superior to standard BP control in reducing LVH
Diabetes Mellitus

- Limited quality evidence to determine a precise BP target in adults with DM
- No RCTs have explicitly
  - Documented whether treatment to an SBP goal <140 mm Hg versus a higher goal improves clinical outcomes in adults with hypertension and DM or
  - Directly evaluated clinical outcomes associated with SBP <130 mm Hg
- Two high-quality systematic reviews of RCTs support an SBP target of <140 mm Hg (Lancet. 2016;387:435-43; CMAJ. 2013;185:949-57)
- A meta-analysis of almost 74,000 patients with DM reported that an SBP <130 mm Hg reduced stroke by 39%, but there was no significant risk reduction for MI (J Hypertens. 2011;29:1253-69)
- SPRINT trial did not include patients with DM
### BP Thresholds and Goals – Comorbidities

<table>
<thead>
<tr>
<th>Clinical Condition</th>
<th>BP Threshold, mm Hg</th>
<th>BP Goal, mm Hg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes mellitus*</td>
<td>≥130/80</td>
<td>&lt;130/80</td>
</tr>
</tbody>
</table>

*Not supported by 2018 ADA guidelines

The vast majority of adults with DM have a 10-year ASCVD risk ≥ 10%, the high risk category that requires antihypertensive drug therapy at BP ≥ 130/80 mm Hg
Diabetes Mellitus

In adults with DM and HTN, antihypertensives should be initiated at a BP of 130/80 mm Hg or higher with a treatment goal of <130/80 mm Hg.

In adults with DM and HTN, all first-line classes of antihypertensive agents (i.e., diuretics, ACE inhibitors, ARBs, and CCBs) are useful and effective.

In adults with DM and HTN, ACE inhibitors or ARBs may be considered in the presence of albuminuria.
Diabetes Mellitus

• BP control is more difficult to achieve in patients with DM than in those without DM, necessitating use of combination therapy in the majority of patients
  – ACE inhibitors and ARBs have the best efficacy among the drug classes on urinary albumin excretion and may be considered as part of the combination for patients with DM
2018 ADA Standards of Medical Care in Diabetes

- Goal blood pressure <140/90 mm Hg
- Lower SBP and DBP targets, such as 130/80 mm Hg, may be appropriate for individuals at high risk of CVD if targets can be achieved without undue treatment burden

- For patients with diabetes but without albuminuria, any of the four classes of BP medications with beneficial CV outcomes may be used.
  - ACEIs
  - ARBs
  - Thiazide-like diuretics
  - Dihydropyridine CCBs

Diabetes Care 2018;41(suppl 1):S1-159.
• An ACEI or ARB, at max tolerated dose, is first-line for HTN in patients with diabetes and a urinary albumin/creatinine ratio:
  – 300 mg/g of creatinine or greater (level A) or
  – 30–299 mg/g of creatinine (level B).
• If one class is not tolerated, the other should be substituted.

• Combinations of 2 or more drugs (ACEI and ARB should not be combined) are usually needed to achieve a goal of <140/90 mm Hg.

• For patients treated with an ACE inhibitor, ARB, or diuretic, serum creatinine/ estimated GFR and serum K levels should be monitored at least annually

Diabetes Care 2018;41(suppl 1):S1-159.
Show of Hands

Do you struggle controlling the blood pressure for your patients with diabetes?

A. Yes, every day
B. Some, depending on the patient
C. No, most of my patients have controlled BP
Hypertension and Chronic Kidney Disease

Joel Marrs, Pharm.D., BCACP, BCPS-AQ Cardiology, CLS, FAHA, FASHP, FCCP, FNLA
Associate Professor
University of Colorado
Aurora, CO
Case: TN

• TN is a 50-year-old African-American man with a history of hypertension, hypercholesterolemia and gout
• Social History: nonsmoker; alcohol 2 to 3 drinks per week; minimal exercise; follows no specific diet
• Medications:
  – Atorvastatin 10 mg daily
  – Lisinopril 40 mg daily
  – Amlodipine 10 mg daily
  – Aspirin 81 mg daily
  – Allopurinol 200 mg daily
Case: TN, continued

• Reports adherence with all medications
• Laboratory values:
  – TC 200 mg/dL, LDL-C 134 mg/dL, HDL 30 mg/dL, TG 180 mg/dL
• Other values:
  – BP 136/84 mm Hg (134/82 when repeated), HR 80 bpm, A1C 5.6%, BMI 29.2 kg/m²; SCr is 1.6 mg/dL (eGFR is 59 mL/min/1.73m²), potassium is 4.9 mEq/L, urinalysis shows albuminuria (150 mg/g)
  – All other labs are normal
  – BP was “high” prior to starting antihypertensive medications
What would you say TN’s BP goal is?

A. < 120/80 mm Hg
B. < 125/85 mm Hg
C. < 130/80 mm Hg
D. < 140/90 mm Hg
Which of the following is the most appropriate change to TN’s regimen?

A. Re-evaluate 1 month after additional healthy lifestyle changes
B. Start HCTZ or chlorthalidone
C. Start labetalol
D. Start spironolactone
Hypertension – Guidelines

• 2012: KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease
• 2014: Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8)
• 2014: ASH/ISH Clinical practice guidelines for the management of hypertension in the community
• 2018: AHA Scientific Statement on Resistant Hypertension
### BP Thresholds and BP Goals for CKD Patients

<table>
<thead>
<tr>
<th>Clinical Condition</th>
<th>BP Threshold, mm Hg</th>
<th>BP Goal, mm Hg</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Specific Co-morbidities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>≥ 130/80</td>
<td>&lt; 130/80</td>
</tr>
<tr>
<td>Chronic kidneys disease post renal transplant</td>
<td>≥ 130/80</td>
<td>&lt; 130/80</td>
</tr>
</tbody>
</table>

Effects of Intensive BP lowering on CV and renal outcomes

• Objective: Assess safety and efficacy of intensive BP-lowering
• Methods:
  – Updated systematic review and meta-analysis
  – More intensive vs. less intensive BP lowering compared
• Trials and Patients:
  – 19 trials including 44,989 participants; no age restrictions
  – 2,496 CV events recorded during mean follow-up of 3.8 yr.
  – Studies ≥6 mos. follow-up
• Outcomes:
• Major CV events, non-vascular and all-cause mortality, stroke, HF, end-stage renal disease (ESRD), adverse events, albuminuria, progression of retinopathy

Effects of Intensive vs. Less Intensive BP Lowering

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Trials (n)</th>
<th>BP Difference (mm Hg)</th>
<th>RR (95% CI)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major CV events†</td>
<td>14</td>
<td>–6.8/–3.5</td>
<td>0.86 (0.78–0.96)</td>
</tr>
<tr>
<td>MI</td>
<td>13</td>
<td>–6.6/–3.4</td>
<td>0.87 (0.76–1.00)</td>
</tr>
<tr>
<td>Stroke</td>
<td>14</td>
<td>–6.8/–3.5</td>
<td>0.78 (0.68–0.90)</td>
</tr>
<tr>
<td>Heart Failure</td>
<td>10</td>
<td>–7.2/–4.0</td>
<td>0.85 (0.66–1.11)</td>
</tr>
<tr>
<td>ESRD</td>
<td>8</td>
<td>–9.4/–5.1</td>
<td>0.90 (0.77–1.06)</td>
</tr>
<tr>
<td>CV Death</td>
<td>13</td>
<td>–6.9/–3.5</td>
<td>0.91 (0.74–1.11)</td>
</tr>
<tr>
<td>Non-CV Death</td>
<td>12</td>
<td>–6.9/–3.6</td>
<td>0.98 (0.86–1.13)</td>
</tr>
<tr>
<td>Overall mortality</td>
<td>19</td>
<td>–6.8/–3.5</td>
<td>0.91 (0.81–1.03)</td>
</tr>
</tbody>
</table>

Favors more intensive BP lowering
Favors less intensive BP lowering

# Antihypertensive Therapy Recommendations: Compelling Indications

<table>
<thead>
<tr>
<th>Clinical Condition</th>
<th>1st Line Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specific Co-morbidities</td>
<td></td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>ACE-I or ARB</td>
</tr>
</tbody>
</table>

**KDIGO*: Albuminuria Influences Treatment**

- Chronic kidney disease, non-dialysis patients

<table>
<thead>
<tr>
<th>Urine Albumin Excretion per 24 hr</th>
<th>BP Goal (mm Hg)</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 30 mg</td>
<td>≤140/90</td>
<td>Not specified</td>
</tr>
<tr>
<td>30 to 300 mg</td>
<td>≤130/80</td>
<td>ACE-I or ARB</td>
</tr>
<tr>
<td>&gt; 300 mg</td>
<td>≤130/80</td>
<td>ACE-I or ARB</td>
</tr>
</tbody>
</table>

- Same suggestions and recommendations provided for patients with diabetes and without, but different cited level of evidence

*KDIGO has noted the publication of the Systolic Blood Pressure Intervention Trial (SPRINT) results and has launched a process to review these and other new data to determine if revisions to its Blood Pressure Guideline are required.*

Hypertension and Heart Failure
Patient Case Continued: AS

• AS is now a 71 year old white woman with diabetes, 4 years since the last time we saw her. About 2 years ago, she developed HFrEF.

• Current Medications:
  – Atorvastatin 80 mg daily
  – Metformin 1 g twice daily
  – Insulin as directed
  – Empagliflozin 25 mg daily
  – Omeprazole 40 mg daily
  – Lisinopril 20 mg/day
  – Furosemide 40 mg twice daily
Patient Case: AS

- Reports adherence with all medications
- Labs and vitals:
  - BP 142/80 mm Hg (138/80 repeat), HR 90 bpm
  - A1C 7.5%; SCr is 1.5 mg/dL (CrCl [adjusted BW] 40.3 ml/min), K 4.3 mEq/L, Na 134 mEq/L, no proteinuria, other labs are normal
  - EF 30%
  - BMI 36.7 kg/m²
What is AS’s BP goal?

A. < 120/80 mm Hg
B. < 130/80 mm Hg
C. < 140/90 mm Hg
D. < 150/90 mm Hg
How should her BP be addressed?

A. Titrate lisinopril to 40 mg/day
B. Start chlorthalidone 12.5 mg/day
C. Start carvedilol 3.125 mg twice daily
D. Start spironolactone 12.5 mg/day
Heart Failure (HFrEF & HFP EF)

• HTN is one of the most important modifiable risk factors
  – Present in 75% of patients with chronic HF
• Patient with HTN have a much higher risk of developing HF than normotensive people
  – Compared with those with an average SBP <120 mm Hg, the adjusted incidence of HF was increased
    • 1.6 times \( \rightarrow \) average SBPs between 120 and 139 mm Hg
    • 2.2 times \( \rightarrow \) average SBPs between 140 and 159 mm Hg
    • 2.6 times \( \rightarrow \) average SBPs \( \geq \)160 mm Hg
• Long-term treatment of both systolic and diastolic HTN reduces the risk of HF by around 50%.
• HTN is an important contributor to acute decompensated HF.
In adults at increased risk of HF, the optimal BP in those with HTN should be <130/80 mm Hg

- In SPRINT, the incidence of HF, a component of the primary outcome, was substantially decreased (hazard ratio: 0.62; 95% confidence interval: 0.45–0.84).
- Meta-analyses of clinical trials have identified a similar beneficial effect of more-intensive BP reduction on the incidence of HF (Hypertens. 2016; 34:613-22; Lancet. 2016;387:957-67), but information from randomized studies to different BP targets is more limited and less compelling (Lancet. 2016;387:435-43)
Heart Failure With Reduced Ejection Fraction

• Approximately 50% of patients with HF have HFrEF
• No RCT evidence is available to support the superiority of one BP-lowering medication for treatment of HFrEF over another.
• Medications with compelling indications for HF that may be used as first-line therapy to treat high BP include
  – ACE inhibitors
  – ARBs
  – Angiotensin receptor–neprilysin inhibitors
  – Mineralocorticoid receptor antagonists
  – Diuretics
  – GDMT beta blockers (carvedilol, metoprolol succinate, or bisoprolol)
Adults with HFrEF and HTN should be prescribed GDMT titrated to attain a BP of <130/80 mm Hg

Nondihydropyridine CCBs are not recommended in the treatment of HTN in adults with HFrEF
Heart Failure With Preserved Ejection Fraction

• Patients with HFP EF (EF from >40% to ≥55%) are usually older women with a history of hypertension.
• Hypertension is the most important cause of HFP EF, with a prevalence of 60% to 89% in large RCTs, epidemiological studies, and HF registries.
• Patients with HFP EF also have an exaggerated hypertensive response to exercise.
• Diuretics are the only drugs used for the treatment of hypertension and HF that can adequately control the fluid retention of HF: must balance hyper- and hypovolemia.
• Renin-angiotensin-aldosterone system inhibition, however, with ACE inhibitor or ARB and especially MRA would represent the preferred choice.
In adults with **HFpEF** with symptoms of volume overload, **diuretics** should be prescribed to control HTN.

| COR | LOE | HFlEF with persistent HTN after managing volume overload, ACE inhibitors or ARBs and beta blockers should be titrated to attain SBP of <130 mm Hg |
For patients at increased risk of developing HF (stage A HF), the optimal blood pressure in those with HTN should be less than 130/80 mm Hg.

- **Rationale:**
  - The SPRINT trial showed that patients with increased CV risk (older than 75 years, established vascular disease, chronic renal disease, or a Framingham Risk greater than 15%), controlling their BP to a goal SBP of <120 mm Hg was associated with a **significantly reduced incidence of HF and CV death**.
  - Because BP measurements taken in the office are about 5–10 mm Hg higher than research measurements, the goal of <130/80 mm Hg is recommended.
  - Note: Targeting a significant reduction in SBP is a **novel strategy** to prevent HF.

Circulation. 2017;136:e137–e161
2017 ACC/AHA/HFSA Focused Update for the Management of HF

• **HFrEF and HTN**
  – SBP goal less than 130 mm Hg
  – Guideline-directed management and titrate dose
    • ACEIs or ARBs or angiotensin receptor-neprilysin inhibitors
    • β-blockers for HF (metoprolol succinate, carvedilol, bisoprolol)
    • Diuretics as needed
    • Aldosterone antagonists when indicated

• **HFpEF and HTN**
  – SBP goal less than 130 mm Hg
  – First, manage volume overload,
  – Then, titrate ACEI or ARB and/or an aldosterone antagonist to goal.

Circulation. 2017;136:e137–e161
Show of Hands

Do you struggle controlling the blood pressure for your patients with heart failure?

A. Yes, every day
B. Some, depending on the patient
C. No, most of my patients have controlled BP
Resistant Hypertension

Joel Marrs, Pharm.D., BCACP, BCPS-AQ Cardiology, CLS, FAHA, FASHP, FCCP, FNLA
Associate Professor
University of Colorado
Aurora, CO
Case: TN
back in clinic (2 years since previous encounter)

• TN is a 52-year-old African-American man with a history of hypertension, hypercholesterolemia, type 2 diabetes mellitus, gout, chronic kidney disease (Stage 3)
• Social History: nonsmoker; alcohol 2 to 3 drinks per week; minimal exercise; follows no specific diet
• Medications:
  – Metformin 1000 mg twice daily
  – Insulin glargine 30 units subcutaneous daily
  – Atorvastatin 40 mg daily
  – Lisinopril 40 mg daily
  – HCTZ 25 mg daily
  – Amlodipine 10 mg daily
  – Aspirin 81 mg daily
  – Allopurinol 200 mg daily
Case: TN, continued

• Reports adherence with all mediations
• Laboratory values:
  – TC 170 mg/dL, LDL-C 105 mg/dL, HDL 33 mg/dL, TG 160 mg/dL
• Other values:
  – BP 138/80 mm Hg (136/80 when repeated), A1C 7.5%, BMI 28.2 kg/m²; SCr is 1.8 mg/dL (eGFR is 52 mL/min/1.73m²), potassium is 4.7 mEq/L, urinalysis shows albuminuria (200 mg/g)
  – All other labs are normal
Does this patient meet the 2018 American Heart Association (AHA) criteria for resistant hypertension?

A. Yes
B. No
C. Unsure
What would you say TN’s BP goal is?

A. < 120/80 mm Hg
B. < 125/85 mm Hg
C. < 130/80 mm Hg
D. < 140/90 mm Hg
Which of the following is the most appropriate change to TN’s regimen?

A. Add hydralazine
B. Change HCTZ to chlorthalidone
C. Add carvedilol or labetalol
D. Add spironolactone
Resistant Hypertension: Detection, Evaluation, and Management

A Scientific Statement From the American Heart Association

Robert M. Carey, MD, FAHA, Chair; David A. Calhoun, MD, FAHA, Vice Chair;
George L. Bakris, MD, FAHA; Robert D. Brook, MD, FAHA; Stacie L. Daugherty, MD, MSPH;
Cheryl R. Dennison-Himmelfarb, PhD, MSN, FAHA; Brent M. Egan, MD;
John M. Flack, MD, MPH, FAHA; Samuel S. Gidding, MD, FAHA; Eric Judd, MD, MS;
Daniel T. Lackland, DrPH, FAHA; Cheryl L. Laffer, MD, PhD, FAHA;
Christopher Newton-Cheh, MD, MPH, FAHA; Steven M. Smith, PharmD, MPH, BCPS;
Sandra J. Taler, MD, FAHA; Stephen C. Textor, MD, FAHA; Tanya N. Turan, MD, FAHA;
William B. White, MD, FAHA; on behalf of the American Heart Association Professional/Public
Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular
and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and
Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care
and Outcomes Research; and Stroke Council
Resistant Hypertension

• American Heart Association (AHA) Definition:
  – “Clinic BP > 130/80 mm Hg and patient taking 3 or more antihypertensive agents (including a long-acting CCB, RAS blocker [ACE-I or ARB] and a diuretic) at maximally tolerated doses.”
  – Also refers to BP controlled with > 4 medications

• Secondary Hypertension
  – Elevated blood pressure as a result from either a co-morbid condition or drug
  – < 10% of overall hypertension
Key Changes in Resistant Hypertension Definition (2008 to 2018)

- BP should be measured and the BP threshold for diagnosis and treatment goals should be in accord with current clinical practice guidelines
- Patients should be taking ≥3 antihypertensive agents
  - Commonly including a long-acting CCB, RAS blocker (ACE-I or ARB), and a diuretic at maximally tolerated doses
- Patients with the white-coat effect should not be included in the definition of resistant HTN
- Diagnosis of resistant HTN requires the exclusion of antihypertensive medication nonadherence
Prevalence of Resistant Hypertension

- **American Heart Association (AHA) Definition:**
  - “Clinic BP > 130/80 mm Hg and patient taking 3 or more antihypertensive agents (including a long-acting CCB, RAS blocker [ACE-I or ARB] and a diuretic) at maximally tolerated doses.
  - Also refers to BP controlled with > 4 medications

- **Secondary Hypertension**
  - Elevated blood pressure as a result from either a co-morbid condition or drug
  - < 10% of overall hypertension

Hypertension. 2018;72:e000–e000. DOI: 10.1161/HYP.0000000000000084.
## Prevalence of Resistant HTN in US

<table>
<thead>
<tr>
<th>Population</th>
<th>Time Period</th>
<th>N</th>
<th>Uncontrolled with ≥ 3 meds (%)</th>
<th>Controlled with ≥ 4 meds (%)</th>
<th>aTRH (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NHANES</td>
<td>1988-1994</td>
<td>2755</td>
<td>8.3</td>
<td>1.1</td>
<td>9.4</td>
</tr>
<tr>
<td>NHANES</td>
<td>1999-2004</td>
<td>3031</td>
<td>8.8</td>
<td>2.9</td>
<td>11.7</td>
</tr>
<tr>
<td>NHANES</td>
<td>2003-2008</td>
<td>3710</td>
<td>----</td>
<td>----</td>
<td>12.8</td>
</tr>
<tr>
<td>NHANES</td>
<td>2005-2008</td>
<td>2586</td>
<td>9.7</td>
<td>4.8</td>
<td>14.5</td>
</tr>
</tbody>
</table>

aTRH = apparent treatment resistant hypertension
Do you utilize home blood pressure monitoring to screen for white coat HTN in your practice?

A Yes

B No
Do you utilize 24hr Ambulatory BP monitoring to screen for white coat HTN in your practice?

A  Yes
B  No
Resistant Hypertension

**Confirm Treatment Resistance**

Clinic BP > 130/80 mm Hg

And

Patient prescribed > 3 BP medications at optimal doses including a diuretic

Or

Clinic BP < 130/80 mm Hg receiving > 4 BP medications

**Exclude Pseudoresistance**

Ensure accurate clinic BP measurement

Confirm adherence to antihypertensive therapy

Perform 24 hour ambulatory BP monitoring to exclude white-coat effect
Resistant Hypertension

**Assess for Secondary Causes**
- Primary aldosteronism
- Renal Parenchymal disease
- Renal artery stenosis
- Pheochromocytoma/paraganglioma
- Cushing syndrome
- Other endocrine causes (Table 3)

**Assess for Target Organ Damage**
- Ocular: fundoscopic exam
- Cardiac: LVH, CAD
- Renal: proteinuria, reduced GFR
- Peripheral artery disease: Ankle/brachial index
Management of Resistant Hypertension

Exclude other causes of HTN
Secondary causes
White-coat effect
Medication nonadherence

Ensure low sodium diet
Maximize lifestyle interventions
≥ 6 hours uninterrupted sleep
Overall dietary pattern
Weight loss
Exercise

Optimize 3-drug regimen
Ensure adherence to 3 drug regimen
Different drug classes (RAS blocker, CCB, diuretic)
Maximum tolerated dose
Diuretic type appropriate for renal function

Step 1

BP not at target

Step 2

Substitute optimally doses thiazide-like diuretic
Change to chlorthalidone or indapamide*

BP not at target

Step 3

Add mineralocorticoid receptor antagonist (MRA)
Spironolactone or eplerenone**

*Efficacy down to eGFR of 30 mL/min/1.73m²
**Use caution if eGFR < 30 mL/min/1.73m²

Hypertension. 2018;72:e000–e000. DOI: 10.1161/HYP.0000000000000084.
Management of Resistant Hypertension

BP not at target ➔ Step 4  *(Expert opinion)*

Add hydralazine*
Dose of 25 mg TID and titrate to maximum dose
If known HFrEF should be given with isosorbide mononitrate 30 mg daily

BP not at target ➔ Step 5  *(Expert opinion)*

Check heart rate
Add Beta Blocker (eg, metoprolol succinate, bisoprolol) or combined Alpha/Beta Blocker (eg, labetalol, carvedilol)
If contraindicated consider Central Alpha Agonist (ie, clonidine patch, guanfacine at bedtime
If these options not tolerated consider once daily diltiazem

BP not at target ➔ Step 6  *(Expert opinion)*

Substitute minoxidil for hydralazine**
Dose of 2.5 mg BID to TID and titrate to maximum dose
If BP still not at target consider referral to hypertension specialist and/or for ongoing experimental studies/trials

*Requires concomitant use of Beta Blocker and diuretic  **Requires concomitant use of Beta Blocker and loop diuretic

Hypertension. 2018;72:e000–e000. DOI: 10.1161/HYP.0000000000000084.
Case: TN back to the patient case

- TN is a 52-year-old African-American man with a history of hypertension, hypercholesterolemia, type 2 diabetes mellitus, gout, chronic kidney disease (Stage 3)
- Social History: nonsmoker; alcohol 2 to 3 drinks per week; minimal exercise; follows no specific diet
- Medications:
  - Metformin 1000 mg twice daily
  - Insulin glargine 30 units subcutaneous daily
  - Atorvastatin 40 mg daily
  - Lisinopril 40 mg daily
  - HCTZ 25 mg daily
  - Amlodipine 10 mg daily
  - Aspirin 81 mg daily
  - Allopurinol 200 mg daily
Case: TN, continued

- Reports adherence with all medications
- Laboratory values:
  - TC 170 mg/dL, LDL-C 105 mg/dL, HDL 33 mg/dL, TG 160 mg/dL
- Other values:
  - BP 138/80 mm Hg (136/80 when repeated), A1C 7.5%, BMI 28.2 kg/m²; SCr is 1.8 mg/dL (eGFR is 52 mL/min/1.73m²), potassium is 4.7 mEq/L, urinalysis shows albuminuria (200 mg/g)
  - All other labs are normal
Which of the following is the most appropriate change to TN’s regimen?

A. Add hydralazine
B. Change HCTZ to chlorthalidone
C. Add carvedilol or labetalol
D. Add spironolactone
1) The goal BP for patients with diabetes is <130/80 mm Hg. All first-line classes of antihypertensive agents (i.e., diuretics, ACE inhibitors, ARBs, and CCBs) are useful and effective. ACE inhibitors or ARBs may be considered in the presence of albuminuria.

2) BP goal for patients with CKD is less than 130/80 mm Hg with a compelling indication to initiate an ACE Inhibitor or ARB first line.

3) The goal BP for patients with heart failure is <130/80 mm Hg. Antihypertensive therapy should be based on type of heart failure and guideline-directed medical therapy.

4) Resistant Hypertension is defined as clinic BP > 130/80 mm Hg and patient taking 3 or more antihypertensive agents (including a long-acting CCB, RAS blocker and a diuretic) at maximally tolerated doses.
At Last! Applying the National Hypertension Guidelines in Special Populations

Karen J. McConnell, Pharm.D., ASH-CHC, BCPS-AQ Cardiology, FCCP
System Director, Clinical Pharmacy Services
Catholic Health Initiatives, Englewood, CO

Joel Marrs, Pharm.D., BCACP, BCPS-AQ Cardiology, CLS, FAHA, FASHP, FCCP, FNLA
Associate Professor
University of Colorado, Aurora, CO